IDEAYA BIOSCIENCE DL-01
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methion… Read more
IDEAYA BIOSCIENCE DL-01 (30J) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, IDEAYA BIOSCIENCE DL-01 (30J) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IDEAYA BIOSCIENCE DL-01 - Net Assets Trend (None–None)
This chart illustrates how IDEAYA BIOSCIENCE DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IDEAYA BIOSCIENCE DL-01 (None–None)
The table below shows the annual net assets of IDEAYA BIOSCIENCE DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to IDEAYA BIOSCIENCE DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
IDEAYA BIOSCIENCE DL-01 Competitors by Market Cap
The table below lists competitors of IDEAYA BIOSCIENCE DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang XCC Group Co Ltd
SHG:603667
|
$2.33 Billion |
|
Chenzhou Jingui Silver Industry Co Ltd
SHE:002716
|
$2.33 Billion |
|
The Chefs Warehouse Inc
NASDAQ:CHEF
|
$2.33 Billion |
|
Parq Arauco
SN:PARAUCO
|
$2.33 Billion |
|
Mitsubishi Logistics Corporation
OTCMKTS:MILGF
|
$2.33 Billion |
|
FI
NEO:FI
|
$2.33 Billion |
|
Yihai Kerry Arawana Holdings Co Ltd
SHE:300999
|
$2.33 Billion |
|
Zhongfu Straits Pingtan Development Co Ltd
SHE:000592
|
$2.33 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IDEAYA BIOSCIENCE DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares IDEAYA BIOSCIENCE DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently IDEAYA BIOSCIENCE DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares IDEAYA BIOSCIENCE DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $338,657,802
- Average return on equity (ROE) among peers: -66.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IDEAYA BIOSCIENCE DL-01 (30J) | €- | N/A | N/A | $2.33 Billion |
| 09R (09R) | $-2.13 Million | 0.00% | 0.00x | $10.61 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $38.55 Billion |
| 1S90 (1S90) | $131.51 Million | -49.87% | 1.70x | $52.41 Million |
| Strategic Partners A/S (1TB0) | $19.25 Million | -1.55% | 0.22x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.50 Million |
| Intervacc AB (publ) (2E9) | $162.33 Million | -46.52% | 0.15x | $3.64 Million |
| 2F5 (2F5) | $-1.76 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $8.56 Million |